Recursion Pharmaceuticals, Inc. Class A Common Stock RXRX
$3.16
-4.53%
at last close
Analyst Consensus
- Consensus Rating
- Moderate Buy (2 Buy · 2 Hold · 0 Sell)
- Average Price Target
- $7.63
- Implied Upside
- +141.3%
- Price Target Range
- $5.50 – $11.00
- Analysts (12 mo)
- 4
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-05-14 | Morgan StanleyVikram Purohit |
Maintains | Equal-weight | $5 → $6 |
| 2026-05-07 | NeedhamGil Blum |
Reiterates | Buy | $8 |
| 2026-02-26 | B of A SecuritiesMichael Ryskin |
Maintains | Neutral | $7 → $6 |
| 2026-02-26 | NeedhamGil Blum |
Reiterates | Buy | $8 |
| 2025-12-17 | JP MorganEric Joseph |
Upgrades | Neutral → Overweight | $10 → $11 |
| 2025-09-11 | NeedhamGil Blum |
Reiterates | Buy | $8 |
| 2025-07-08 | NeedhamGil Blum |
Reiterates | Buy | $8 |
| 2025-07-03 | Morgan StanleyVikram Purohit |
Assumes | Equal-weight | $5 |
| 2025-06-16 | Morgan StanleyVikram Purohit |
Maintains | Equal-weight | $8 → $5 |
| 2025-05-06 | NeedhamGil Blum |
Maintains | Buy | $11 → $8 |
| 2025-04-10 | Morgan StanleyVikram Purohit |
Maintains | Equal-weight | $10 → $8 |
| 2025-04-08 | NeedhamGil Blum |
Reiterates | Buy | $11 |
| 2025-02-28 | Leerink PartnersMani Foroohar |
Maintains | Market perform | $7 → $6 |
| 2025-02-06 | NeedhamGil Blum |
Reiterates | Buy | $11 |
| 2025-01-08 | KeybancScott Schoenhaus |
Maintains | Overweight | $12 → $10 |
| 2024-12-11 | NeedhamGil Blum |
Reiterates | Buy | $11 |
| 2024-11-20 | NeedhamGil Blum |
Reiterates | Buy | $11 |
| 2024-11-07 | NeedhamGil Blum |
Reiterates | Buy | $11 |
| 2024-09-04 | NeedhamGil Blum |
Maintains | Buy | $16 → $11 |
| 2024-09-03 | JefferiesDennis Ding |
Maintains | Hold | $8 → $6 |
| 2024-09-03 | Leerink PartnersMani Foroohar |
Maintains | Market perform | $9 → $8 |
| 2024-08-09 | NeedhamGil Blum |
Maintains | Buy | $17 → $16 |
| 2024-07-11 | KeybancScott Schoenhaus |
Maintains | Overweight | $16 → $12 |
| 2024-06-25 | NeedhamGil Blum |
Reiterates | Buy | $17 |
| 2024-05-10 | NeedhamGil Blum |
Reiterates | Buy | $17 |
| 2024-04-09 | NeedhamGil Blum |
Reiterates | Buy | $17 |
| 2024-03-04 | KeybancScott Schoenhaus |
Maintains | Overweight | $15 → $16 |
| 2024-02-28 | NeedhamGil Blum |
Maintains | Buy | $15 → $17 |
| 2024-01-26 | TD CowenSteven Mah |
Initiates coverage on | Market perform | — |
| 2024-01-17 | NeedhamGil Blum |
Reiterates | Buy | $15 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $3.16
- Market Cap
- $1.76 billion
- 52-Week Range
- $2.77 – $7.18
- Average Volume
- 19.05 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.